Xelpmoc's operating margin falls to -262.67% as costs rise
Revenue declined qoq, while management said it is pursuing corporate-sector revenue and profitability through its own products and services.
Filed 13 Nov 2026, 11:41 IST · Xelpmoc Design and Tech Ltd (XELPMOC)
Key takeaways
- Revenue fell 10.42% qoq while expenses rose 16.42%, pushing operating margin down 84.24 percentage points to -262.67%.
- Net loss was nearly unchanged at Rs 2.21 cr because a 23.65-percentage-point tax-rate swing cushioned the weaker pre-tax result.
- Xelpmoc's operating margin was 277.87 percentage points below the 15.2% median of 89 reported IT peers.
Price around the results
Costs widened the operating loss
Consolidated revenue declined 10.42% qoq to Rs 0.86 cr, even as expenses increased 16.42% to Rs 3.12 cr. Costs therefore grew faster than revenue, worsening the operating loss to Rs 2.26 cr and cutting operating margin by 84.24 percentage points. The company told investors it is focusing on generating revenue from the corporate sector.
Other income did not offset the core loss
Other income rose 47.62% qoq to Rs 0.31 cr, but represented -13.9% of pre-tax profit because pre-tax profit remained a loss; it did not provide a meaningful earnings offset. The pre-tax loss widened to Rs 2.23 cr, while the lower tax charge and a 23.65-percentage-point tax-rate swing kept net loss almost unchanged at Rs 2.21 cr. This is the second reported quarter in the trend, so the margin deterioration is sequential rather than a multi-quarter pattern.
Operating margin ranked last among reported IT peers
Among 89 Information Technology peers that had reported the same quarter, Xelpmoc's -262.67% operating margin was 277.87 percentage points below the 15.2% sector median. It ranked first from the bottom on this measure. The comparison underscores that the quarter's pressure was concentrated in Xelpmoc's operating economics.
Products and portfolio activity remain the stated focus
Management said its primary goal is to achieve profitability as early as possible through its own products and services. The presentation said RELY launched during the quarter and onboarded three customers, while DocuXray demonstrated its technical capabilities. Management also said Biome increased its OsteoForge investment to INR 4 Cr for a 10% combined stake, and that OsteoForge received pilot-trial approval and signed two institutional MoUs.
Initial stock response was limited
At the initial reaction point on the filing date, the stock was down 0.23%, with a 0.38% opening gap and relative performance of 0.39%. The response was recorded before a complete post-results trading history was available, so it does not establish a typical reaction for this stock.
Q2FY27 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q2FY27 | Q1FY27 | QoQ |
|---|---|---|---|
| Revenue | ₹1 cr | ₹1 cr | -10.42% |
| Other income | ₹0 cr | ₹0 cr | +47.62% |
| Expenses | ₹3 cr | ₹3 cr | +16.42% |
| Operating profit | ₹-2 cr | ₹-2 cr | -31.40% |
| Operating margin (%) | -262.67% | -178.43% | — |
| Interest | ₹0 cr | ₹0 cr | -100.00% |
| Depreciation | ₹0 cr | ₹0 cr | -3.45% |
| Profit before tax | ₹-2 cr | ₹-2 cr | -23.89% |
| Tax | ₹-0 cr | ₹0 cr | — |
| Net profit | ₹-2 cr | ₹-2 cr | -0.45% |
| EPS (₹) | ₹-1.49 | ₹-1.49 | +0.00% |
Operating margin of -262.67% compares with a Information Technology sector median of 15.20% across 89 peers that have reported Q2FY27.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -0.23% | +0.39% |
Volume on the results session was 0.41× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- DocuXray demonstrated strong technical capabilities during the quarter.
- RELY went live during the quarter and onboarded three customers.
Guidance & outlook
- The company is focusing on generating revenue from the corporate sector.
- The company aims to achieve profitability as early as possible through its own products and services.
Expansion
- Biome increased its OsteoForge investment to INR 4 Cr for a 10% combined stake.
- Biome is evaluating strategic investments in new EIR spinouts across enterprise AI and collections intelligence.
- OsteoForge received pilot-trial approval, signed two institutional MoUs and progressed toward manufacturing readiness.
New products
- The company launched RELY, an Agetech platform for assisted and senior living.
New initiatives
- Supr Agent joined Biome’s portfolio as an agentic AI platform for BFSI workflows across voice, WhatsApp and SMS.
- OsteoForge signed two new MoUs with medical institutions for upcoming pivotal trials.
- DocuXray uses an independent, locally deployable AI engine with data extraction, workflow automation and rules-based validation.
Problems & risks
- Legal teams face repetitive, time-consuming and costly manual contract review, data extraction and risk identification.
What to watch
- Whether revenue from the corporate sector lifts consolidated revenue above Rs 0.86 cr.
- Whether operating margin improves from -262.67% as expenses moderate from Rs 3.12 cr.
- Whether RELY builds on the three customers onboarded during the quarter.